|Bid||130.45 x 300|
|Ask||133.01 x 300|
|Day's Range||131.95 - 134.30|
|52 Week Range||114.07 - 139.37|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.06%|
U.S. small business activity improves in July; beats estimates.
Since demand from the target population for prophylaxis is rising rapidly, Bioverativ’s Alprolix and Eloctate are expected to see solid demand trends in 2017.
About 40% of patients succumb to heart failure within five years. Abiomed believes that it is reperfusion injuries that cause these problems.